Cytokinetics (CYTK) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$1.50
- EPS estimate
- −$1.63
- EPS surprise
- +7.87%
- Revenue surprise
- +62.75%
- Revenue
- $28.6M
- Revenue estimate
- $17.6M
- Reported
- Aug 6, 2026
Cytokinetics reported Q2 2026 results on August 6, 2026. The company posted a loss of $1.50 per share, narrower than the $1.63 loss analysts expected, which the source records as a 7.87% beat. Revenue was $28.6 million against a $17.6 million consensus, a 62.75% beat. Compared with Q2 2025, the loss per share widened from $1.12, and revenue was lower than the $66.8 million reported a year earlier.
Cytokinetics reported a loss in every one of the 20 quarters in the table. Annual losses per share were $4.25 in 2022, $5.45 in 2023, $5.26 in 2024 and $6.53 in 2025. The first half of 2026 adds up to a loss of $3.17. Revenue has been small and irregular, ranging from $249,000 in Q2 2024 to $89.0 million in Q2 2022. The last three quarters show $17.8 million, $19.4 million and $28.6 million. Cytokinetics beat the EPS estimate six times over the last 20 quarters and missed 14 times.
Cytokinetics reported Q3 between November 2 and November 7 in each of the past five years. That points to early November 2026 for the next report. It will show whether revenue keeps rising and how the loss compares.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 6, 2026 | −$1.63 | −$1.50 | +7.87% | $28.6M | SEC |
| Q1 2026 | May 5, 2026 | −$1.65 | −$1.67 | −1.07% | $19.4M | SEC |
| Q4 2025 | Feb 24, 2026 | −$1.56 | −$1.50 | +4.12% | $17.8M | SEC |
| Q3 2025 | Nov 5, 2025 | −$1.57 | −$2.55 | −62.36% | $1.9M | SEC |
| Q2 2025 | Aug 7, 2025 | −$1.43 | −$1.12 | +21.66% | $66.8M | SEC |
| Q1 2025 | May 6, 2025 | −$1.37 | −$1.36 | +0.69% | $1.6M | SEC |
| Q4 2024 | Feb 27, 2025 | −$1.19 | −$1.26 | −5.62% | $16.9M | SEC |
| Q3 2024 | Nov 7, 2024 | −$1.23 | −$1.36 | −10.16% | $463,000.00 | SEC |
| Q2 2024 | Aug 8, 2024 | −$1.06 | −$1.31 | −23.98% | $249,000.00 | SEC |
| Q1 2024 | May 8, 2024 | −$1.14 | −$1.33 | −16.29% | $835,000.00 | SEC |
| Q4 2023 | Feb 27, 2024 | −$0.96 | −$1.38 | −43.97% | $1.7M | SEC |
| Q3 2023 | Nov 2, 2023 | −$0.74 | −$1.35 | −81.74% | $378,000.00 | SEC |
| Q2 2023 | Aug 3, 2023 | −$1.14 | −$1.34 | −17.61% | $867,000.00 | SEC |
| Q1 2023 | May 4, 2023 | −$1.20 | −$1.38 | −15.06% | $4.6M | SEC |
| Q4 2022 | Mar 1, 2023 | −$1.21 | −$1.45 | −20.22% | $2.0M | SEC |
| Q3 2022 | Nov 3, 2022 | −$1.16 | −$1.52 | −30.61% | $2.5M | SEC |
| Q2 2022 | Aug 4, 2022 | −$1.03 | −$0.23 | +77.66% | $89.0M | SEC |
| Q1 2022 | May 4, 2022 | −$0.94 | −$1.05 | −11.28% | $1.1M | — |
| Q4 2021 | Feb 24, 2022 | −$0.85 | −$0.36 | +57.56% | $55.6M | — |
| Q3 2021 | Nov 3, 2021 | −$0.78 | −$0.95 | −22.42% | $5.4M | — |
Quarterly revenue
Frequently asked questions
When did Cytokinetics (CYTK) last report earnings?
Cytokinetics last reported on Aug 6, 2026, covering fiscal Q2 2026.
Did CYTK beat earnings estimates?
Yes. Cytokinetics reported EPS of −$1.50 for Q2 2026 against a −$1.63 estimate — a 7.87% beat.
How much revenue did CYTK report last quarter?
Cytokinetics reported $28.6M in revenue for Q2 2026, against a consensus estimate of $17.6M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.